Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $4.60.
Actively observing the price movement in the last trading, the stock closed the session at $4.60. The value of beta (5-year monthly) was 1.92. Referring to stock’s 52-week performance, its high was $9.06, and the low was $4.58. On the whole, BCRX has fluctuated by -11.71% over the past month.
With the market capitalization of Biocryst Pharmaceuticals Inc. currently standing at about $948.29 million, investors are eagerly awaiting this quarter’s results, scheduled for May 01, 2024 – May 06, 2024.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that BCRX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BCRX currently trading nearly -9.56% and -14.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.39, while the 7-day volatility ratio is showing 5.00% which for the 30-day chart, stands at 5.48%. Furthermore, Biocryst Pharmaceuticals Inc. (BCRX)’s beta value is 1.94, and its average true range (ATR) is 0.29.
A comparison of Biocryst Pharmaceuticals Inc. (BCRX) with its peers suggests the former has fared considerably weaker in the market. BCRX showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -44.58%%.
Data on historical trading for Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) indicates that the trading volumes over the past 10 days have averaged 3.34 million and over the past 3 months, they’ve averaged 3.36 million. According to company’s latest data on outstanding shares, there are 205.77 million shares outstanding.
Nearly 3.69% of Biocryst Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 84.63% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 30.55 million shares as on Mar 15, 2024, resulting in a short ratio of 9.31. According to the data, the short interest in Biocryst Pharmaceuticals Inc. (BCRX) stood at 14.82% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 29.41 million. The stock has fallen by -23.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BCRX stock heading into the next quarter.
